Publications

Hugo ten Cate, M.D., Ph.D. (2021). Surviving Covid-19 with Heparin? The New England Journal of Medicine; DOI: 10.1056/NEJMe2111151

The ATTACC, ACTIV-4a, and REMAP-CAP Investigators (2021). Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. The New England Journal of Medicine; DOI: 10.1056/NEJMoa2105911

The REMAP-CAP, ACTIV-4a, and ATTACC Investigators (2021). Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. The New England Journal of Medicine; DOI: 10.1056/NEJMoa2103417

Lawler, P., Goligher, E., Berger, J., Neal, M., McVerry, B., Nicolau, J., Gong, M., Carrier, M., Rosenson, R., Reynolds, H., Turgeon, A., Escobedo, J., Huang, D., Bradbury, C., Houston, B., Kornblith, L., Kumar, A., Kahn, S., Cushman, M.,… Zarychanski, R. (2021). Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19. medRXiv; DOI: 10.1101/2021.05.13.21256846

The REMAP-CAP, ACTIV-4a, ATTACC Investigators, Ryan Zarychansk. (2021). Therapeutic Anticoagulation in Critically Ill Patients with Covid-19 – Preliminary Report. medRXiv; DOI: 10.1101/2021.03.10.21252749

Houston, B., Lawler, P., Goligher, E., Farkouh, M., Bradbury, C., Carrier, M., Dzavik, V., Fergusson, D.,Fowler, R., Galanaud, J., Gross, P., McDonald, E., Husain, M., Kahn, S., Kumar, A., Marshall, J., Murthy, S.,Slutsky, A., Turgeon, A.,... Zarychanski, R. (2020). Anti-Thrombotic Therapy to Ameliorate Complicationsof COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial.Clinical Trials (London, England), p.17407745209438

CMAJ Podcasts: Lucas C. Godoy, Ewan C. Goligher, Patrick R. Lawler, Arthur S. Slutsky and Ryan Zarychanski | CMAJ October 05, 2020 192 (40) E1156-E1161; DOI: https://doi.org/10.1503/cmaj.201240